医薬品有効成分市場：タイプ、合成、メーカー、治療用途別-2025年～2030年世界予測

医薬品有効成分市場は、2023年に1,527億7,000万米ドルと評価され、2024年には1,643億4,000万米ドルに達すると予測され、CAGR 7.88%で成長し、2030年には2,599億7,000万米ドルに達すると予測されています。

医薬品有効成分（API）は医薬品の重要な構成要素であり、医薬品の意図した効果をもたらします。原薬の範囲は、医薬品製剤における必要性、疾病治療における幅広い用途、製薬、バイオテクノロジー、受託製造組織における最終用途を包含しています。慢性疾患の新興国市場の拡大、高齢者人口の増加、医薬品開発技術の進歩はAPI市場の極めて重要な成長要因です。生物製剤の採用増加や特殊医薬品の需要急増は注目すべき機会です。特許の失効、ジェネリック医薬品の増加、個別化医療への注力といった要因が市場の進展をさらに後押ししています。医薬品の有効性と安全性を重視する規制上の義務付けは、製造プロセスの革新を促し、特にグリーンケミストリーやバイオテクノロジーの進歩における機会を促進しています。

しかし、市場に課題がないわけではないです。厳しい規制の枠組み、高い製造コスト、複雑な製造工程が大きなハードルとなっています。特に地政学的緊張や限られた数のサプライヤーへの依存に起因する原料供給の途絶の脅威は、市場成長の妨げとなる可能性があります。さらに、各地域でコンプライアンス規範が進化しているため、常に適応する必要があり、企業の業務効率に影響を与える可能性があります。新たな機会を活かすため、企業は持続可能で環境に優しい製造プロセスの開発に投資し、AIと機械学習を活用して生産を最適化し、品質管理を強化すべきです。バイオシミラーと新規ドラッグデリバリーシステムの追求は競争優位性をもたらします。

原薬市場は非常にダイナミックであり、製品ポートフォリオと地理的アウトリーチの拡大を目指した戦略的提携や合併が特徴です。研究開発、特に核酸やペプチドのような非伝統的なAPIに重点を置くことは、技術革新の有望な分野であることを示します。この業界は技術集約型である一方、規制の変化や市場の需要への適応力でも繁栄しており、長期的な成長を維持するためには、リスク管理と生産適応力において積極的なアプローチを維持することが不可欠です。

市場力学：急速に進化する医薬品有効成分市場の主要市場インサイトを公開

医薬品有効成分市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 製薬企業による研究開発活動の活発化
  • 高度な医薬品製造技術に対する政府の支援
  • CDMOによる医薬品製造能力強化のための投資の増加
• 市場抑制要因
  • 高度なAPI技術に伴う高コスト
• 市場機会
  • 医薬品有効成分技術における技術進歩
  • 新規治療薬開発のための微粉化技術の採用
• 市場の課題
  • 望ましい粒度分布の達成と維持に伴う技術的複雑性

ポーターの5つの力：医薬品有効成分市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：医薬品有効成分市場における外部からの影響の把握

外部マクロ環境要因は、医薬品有効成分市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析医薬品有効成分市場における競合情勢の把握

医薬品有効成分市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス医薬品有効成分市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、医薬品有効成分市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨医薬品有効成分市場における成功への道筋を描く

医薬品有効成分市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 製薬会社の研究開発活動の増加
    • 先進的な医薬品製造技術に対する政府の支援
    • CDMOによる医薬品製造能力の強化に向けた投資の増加
  • 抑制要因
    • 高度なAPIテクノロジーに関連する高コスト
  • 機会
    • 医薬品有効成分技術の技術的進歩
    • 新規医薬品の開発に向けた微粉化技術の採用
  • 課題
    • 望ましい粒度分布を達成し維持することに関連する技術的な複雑さ
• 市場セグメンテーション分析
  • タイプ：研究開発費の削減により汎用APIのアクセシビリティが向上
  • 治療への応用：糖尿病の世界の蔓延により、医薬品有効成分の研究開発が促進される
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 医薬品有効成分市場：タイプ別

• 一般的な医薬品有効成分
• 革新的な医薬品有効成分

第7章 医薬品有効成分市場：合成別

• バイオテクノロジー医薬品有効成分
• 合成医薬品有効成分

第8章 医薬品有効成分市場：メーカー別

• キャプティブ APIメーカー
• マーチャント APIメーカー

第9章 医薬品有効成分市場：治療用途別

• 心血管疾患
• 伝染病
• 糖尿病
• 腫瘍学
• 疼痛管理
• 呼吸器疾患

第10章 南北アメリカの医薬品有効成分市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の医薬品有効成分市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの医薬品有効成分市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • イーライリリー、糖尿病・肥満治療薬のAPI製造強化に向け記録的な90億米ドルを投資
  • 米国の協力により、ミズーリ州の新しい腫瘍学施設で必須の神経膠芽腫薬の生産が強化される
  • ノラムコグループ、北米の医薬品サプライチェーンを強化
• 戦略分析と提言

企業一覧

• Abbvie Inc.
• API Pharma Tech
• AstraZeneca PLC
• Aurobindo Pharma Limited
• BASF SE
• BDR Pharmaceuticals Internationals Pvt. Ltd.
• Bristol-Myers Squibb Company
• C.H. Boehringer Sohn AG & Co. KG
• Cipla, Inc.
• Dr. Reddy's Laboratories Ltd
• ELI Lilly and Company
• F. Hoffmann-La Roche AG
• Glaxosmithkline PLC
• Lonza Group Ltd.
• Lupin Ltd.
• Merck & Co., Inc.
• Novartis International AG
• Pfizer, Inc.
• Sanofi S.A.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET RESEARCH PROCESS
• FIGURE 2. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET DYNAMICS
• TABLE 7. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CAPTIVE API MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MERCHANT API MANUFACTURERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COMMUNICABLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 38. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 39. CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 60. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 61. CHINA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 64. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 65. INDIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 133. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 134. ITALY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 149. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 150. POLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 153. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 154. QATAR ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY SYNTHESIS, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY MANUFACTURER, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
• TABLE 191. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, FPNV POSITIONING MATRIX, 2023

The Active Pharmaceutical Ingredients Market was valued at USD 152.77 billion in 2023, expected to reach USD 164.34 billion in 2024, and is projected to grow at a CAGR of 7.88%, to USD 259.97 billion by 2030.

Active Pharmaceutical Ingredients (APIs) form the critical components in pharmaceuticals, responsible for the intended effects of drugs. The scope of APIs encompasses their necessity in drug formulation, wide-ranging applications across disease treatments, and end-use in pharmaceuticals, biotechnology, and contract manufacturing organizations. The growing prevalence of chronic diseases, increasing geriatric population, and advancements in drug development technologies are pivotal growth factors in the API market. The rising adoption of biologics and the surge in demand for specialty medicines present notable opportunities. Factors such as patent expirations, increased generic drug production, and a focus on personalized medicine further bolster market advancements. Regulatory mandates that stress drug efficacy and safety are driving innovations in manufacturing processes, fostering opportunities especially within green chemistry and biotechnological advancements.

However, the market is not devoid of challenges. Stringent regulatory frameworks, high production costs, and complex manufacturing processes pose significant hurdles. The threat of raw material supply disruptions, particularly due to geopolitical tensions and dependency on a limited number of suppliers, can hinder market growth. Moreover, evolving compliance norms across regions necessitate constant adaptation, potentially impacting firms' operational efficiencies. To capitalize on emerging opportunities, companies should invest in the development of sustainable and eco-friendly manufacturing processes, leveraging AI and machine learning to optimize production and enhance quality control. Pursuing biosimilars and novel drug delivery systems can offer competitive advantages.

The API market is highly dynamic, characterized by strategic collaborations and mergers aimed at expanding product portfolios and geographical outreach. Emphasis on research and development, particularly in non-traditional APIs like nucleic acids and peptides, marks a promising area for innovation. While being technology-intensive, the industry also thrives on adaptability to regulatory changes and market demands, making it crucial for players to maintain a proactive approach in risk management and production adaptability to sustain long-term growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Active Pharmaceutical Ingredients Market

The Active Pharmaceutical Ingredients Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing research & development activities by pharmaceutical companies
  • Government support for advanced pharmaceutical manufacturing techniques
  • Rising investments to enhance drug manufacturing capabilities by CDMOs
• Market Restraints
  • High cost associated with advanced API technologies
• Market Opportunities
  • Technological advancements in active pharmaceutical ingredients techniques
  • Adoption of micronization techniques to develop novel drug therapeutics
• Market Challenges
  • Technical complexity associated with achieving and maintaining the desired particle size distribution

Porter's Five Forces: A Strategic Tool for Navigating the Active Pharmaceutical Ingredients Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Active Pharmaceutical Ingredients Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Active Pharmaceutical Ingredients Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Active Pharmaceutical Ingredients Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Active Pharmaceutical Ingredients Market

A detailed market share analysis in the Active Pharmaceutical Ingredients Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Active Pharmaceutical Ingredients Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Active Pharmaceutical Ingredients Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Active Pharmaceutical Ingredients Market

A strategic analysis of the Active Pharmaceutical Ingredients Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Active Pharmaceutical Ingredients Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., API Pharma Tech, AstraZeneca PLC, Aurobindo Pharma Limited, BASF SE, BDR Pharmaceuticals Internationals Pvt. Ltd., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Cipla, Inc., Dr. Reddy's Laboratories Ltd, ELI Lilly and Company, F. Hoffmann-La Roche AG, Glaxosmithkline PLC, Lonza Group Ltd., Lupin Ltd., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Active Pharmaceutical Ingredients Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Generic Active Pharmaceutical Ingredients and Innovative Active Pharmaceutical Ingredients.
• Based on Synthesis, market is studied across Biotech Active Pharmaceutical Ingredients and Synthetic Active Pharmaceutical Ingredients.
• Based on Manufacturer, market is studied across Captive API Manufacturers and Merchant API Manufacturers.
• Based on Therapeutic Application, market is studied across Cardiovascular Diseases, Communicable Diseases, Diabetes, Oncology, Pain Management, and Respiratory Diseases.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing research & development activities by pharmaceutical companies
    • 5.1.1.2. Government support for advanced pharmaceutical manufacturing techniques
    • 5.1.1.3. Rising investments to enhance drug manufacturing capabilities by CDMOs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with advanced API technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in active pharmaceutical ingredients techniques
    • 5.1.3.2. Adoption of micronization techniques to develop novel drug therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Technical complexity associated with achieving and maintaining the desired particle size distribution
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Increasing accessibility of generic APIs due to eliminated R&D expenses
  • 5.2.2. Therapeutic Application: Increasing prevalence of diabetes globally boost the R&D for active pharmaceutical ingredients
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Active Pharmaceutical Ingredients Market, by Type

• 6.1. Introduction
• 6.2. Generic Active Pharmaceutical Ingredients
• 6.3. Innovative Active Pharmaceutical Ingredients

7. Active Pharmaceutical Ingredients Market, by Synthesis

• 7.1. Introduction
• 7.2. Biotech Active Pharmaceutical Ingredients
• 7.3. Synthetic Active Pharmaceutical Ingredients

8. Active Pharmaceutical Ingredients Market, by Manufacturer

• 8.1. Introduction
• 8.2. Captive API Manufacturers
• 8.3. Merchant API Manufacturers

9. Active Pharmaceutical Ingredients Market, by Therapeutic Application

• 9.1. Introduction
• 9.2. Cardiovascular Diseases
• 9.3. Communicable Diseases
• 9.4. Diabetes
• 9.5. Oncology
• 9.6. Pain Management
• 9.7. Respiratory Diseases

10. Americas Active Pharmaceutical Ingredients Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Active Pharmaceutical Ingredients Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Active Pharmaceutical Ingredients Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Eli Lilly's Record-Breaking USD 9 Billion Investment to Boost API Manufacturing for Diabetes and Obesity Treatments
  • 13.3.2. United States Collaboration Enhances Production of Essential Glioblastoma Drug with New Oncology Suite in Missouri
  • 13.3.3. Noramco Group Strengthening North America's Pharmaceutical Supply Chain
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie Inc.
• 2. API Pharma Tech
• 3. AstraZeneca PLC
• 4. Aurobindo Pharma Limited
• 5. BASF SE
• 6. BDR Pharmaceuticals Internationals Pvt. Ltd.
• 7. Bristol-Myers Squibb Company
• 8. C.H. Boehringer Sohn AG & Co. KG
• 9. Cipla, Inc.
• 10. Dr. Reddy's Laboratories Ltd
• 11. ELI Lilly and Company
• 12. F. Hoffmann-La Roche AG
• 13. Glaxosmithkline PLC
• 14. Lonza Group Ltd.
• 15. Lupin Ltd.
• 16. Merck & Co., Inc.
• 17. Novartis International AG
• 18. Pfizer, Inc.
• 19. Sanofi S.A.
• 20. Sun Pharmaceutical Industries Ltd
• 21. Teva Pharmaceutical Industries Ltd
• 22. Viatris Inc.